Citadel Advisors
HUMA icon

Citadel Advisors’s Humacyte HUMA Stock Holding History

Citadel Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,566,431
Closed -$1.63M – 13527
2025
Q4 		$1.5M Buy
1,566,431
+673,479
+75% +$954K ﹤0.01% 6505
2025
Q3 		$1.55M Buy
892,952
+268,194
+43% +$525K ﹤0.01% 6586
2025
Q2 		$1.31M Sell
624,758
-2,287,143
-79% -$4.39M ﹤0.01% 6524
2025
Q1 		$4.96M Buy
2,911,901
+2,740,439
+1,598% +$10.3M ﹤0.01% 3884
2024
Q4 		$866K Buy
171,462
+18,318
+12% +$90.6K ﹤0.01% 7353
2024
Q3 		$833K Buy
153,144
+109,242
+249% +$720K ﹤0.01% 7227
2024
Q2 		$211K Sell
43,902
-210,349
-83% -$1.09M ﹤0.01% 9815
2024
Q1 		$791K Buy
254,251
+69,121
+37% +$232K ﹤0.01% 7420
2023
Q4 		$526K Sell
185,130
-93,457
-34% -$240K ﹤0.01% 7986
2023
Q3 		$816K Buy
278,587
+239,498
+613% +$792K ﹤0.01% 6998
2023
Q2 		$112K Buy
+39,089
New +$141K ﹤0.01% 10758
2023
Q1 		– Sell
-510
Closed -$1.08K – 15040
2022
Q4 		$1.08K Sell
510
-168,468
-100% -$511K ﹤0.01% 14528
2022
Q3 		$551K Sell
168,978
-30,605
-15% -$117K ﹤0.01% 8244
2022
Q2 		$640K Buy
199,583
+147,415
+283% +$820K ﹤0.01% 8086
2022
Q1 		$368K Buy
52,168
+32,275
+162% +$188K ﹤0.01% 10119
2021
Q4 		$144K Buy
+19,893
New +$197K ﹤0.01% 12315

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's HUMA Position: Q1 2026 in Review

Citadel Advisors sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 1,566,431 shares — an estimated $1.63M sold.

Citadel Advisors first reported a position in HUMA in Q4 2021 and held it in 16 quarters. The position peaked at $4.96M in Q1 2025. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Citadel Advisors reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,566,431 Humacyte shares in Q1 2026, an estimated $1.63M.
  • Citadel Advisors first reported a position in Humacyte in Q4 2021 and held it in 16 quarters.
  • Citadel Advisors's Humacyte position peaked at $4.96M in Q1 2025.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.